{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T01:31:06Z","timestamp":1789781466035,"version":"4.0.1"},"reference-count":8,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2011,7,1]],"date-time":"2011-07-01T00:00:00Z","timestamp":1309478400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,7,1]],"date-time":"2011-07-01T00:00:00Z","timestamp":1309478400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2011,7]]},"DOI":"10.1136\/ard.2010.137935","type":"journal-article","created":{"date-parts":[[2010,11,11]],"date-time":"2010-11-11T01:59:59Z","timestamp":1289440799000},"page":"1340-1341","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"title":["The monoclonal anti-CD25 antibody basiliximab for the treatment of progressive systemic sclerosis: an open-label study"],"prefix":"10.1016","volume":"70","author":[{"given":"M O","family":"Becker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Br\u00fcckner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H U","family":"Scherer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N","family":"Wassermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J Y","family":"Humrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L G","family":"Hanitsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Kawald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Hanke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G R","family":"Burmester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Riemekasten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/ard.2010.137935_bib1","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1097\/BOR.0b013e3283310d57","article-title":"Disease-modifying treatment in systemic sclerosis: current status","volume":"21","author":"Quillinan","year":"2009","journal-title":"Curr Opin Rheumatol"},{"key":"10.1136\/ard.2010.137935_bib2","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1111\/j.1365-2133.2007.07827.x","article-title":"Sclerodermatous graft-versus-host disease: clinical spectrum and therapeutic challenges","volume":"156","author":"White","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1136\/ard.2010.137935_bib3","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1111\/j.1365-2141.2005.05631.x","article-title":"Efficacy of the interleukin-2 receptor antagonist basiliximab in steroid-refractory acute graft-versus-host disease","volume":"130","author":"Schmidt-Hieber","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1136\/ard.2010.137935_bib4","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/0090-1229(90)90147-I","article-title":"Soluble and cellular markers of immune activation in patients with systemic sclerosis","volume":"56","author":"Degiannis","year":"1990","journal-title":"Clin Immunol Immunopathol"},{"key":"10.1136\/ard.2010.137935_bib5","first-page":"646","article-title":"Soluble serum interleukin 2 receptors in patients with systemic sclerosis","volume":"23","author":"Steen","year":"1996","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2010.137935_bib6","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1136\/ard.2005.046938","article-title":"Targeting activated T cells: successful use of anti-CD25 monoclonal antibody basiliximab in a patient with systemic sclerosis","volume":"65","author":"Scherer","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2010.137935_bib7","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1056\/NEJMoa055120","article-title":"Cyclophosphamide versus placebo in scleroderma lung disease","volume":"354","author":"Tashkin","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1136\/ard.2010.137935_bib8","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1002\/art.24681","article-title":"Course of the modified Rodnan skin thickness score in systemic sclerosis clinical trials: analysis of three large multicenter, double-blind, randomized controlled trials","volume":"60","author":"Amjadi","year":"2009","journal-title":"Arthritis Rheum"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724100659?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724100659?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ard.2010.137935","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T05:28:58Z","timestamp":1737437338000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496724100659"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,7]]},"references-count":8,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2011,7]]}},"alternative-id":["S0003496724100659"],"URL":"https:\/\/doi.org\/10.1136\/ard.2010.137935","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2011,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The monoclonal anti-CD25 antibody basiliximab for the treatment of progressive systemic sclerosis: an open-label study","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ard.2010.137935","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Published by Elsevier Inc. For permission to use (where not already granted under a licence) please go to http:\/\/group.bmj.com\/group\/rights-licensing\/permissions. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}